Takeda Pharmaceutical Co. Ltd. Sponsored ADR (TSE:4502) is advancing oral TYK2 inhibitor zasocitinib toward a U.S. launch in H1 2027 after strong Phase III psoriasis PASI-100 results versus deucravacitinib, while Q1 FY2026 revenue rose and full-year guidance was reaffirmed despite lower core EPS an…
Explore more price target data and ratings for Takeda Pharmaceutical Company Limited on the Forecasts tab, and track all previous and future analyst recommendations for Takeda Pharmaceutical Company Limited in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactS…
Explore more price target data and ratings for Takeda Pharmaceutical Company Limited on the Forecasts tab, and track all previous and future analyst recommendations for Takeda Pharmaceutical Company Limited in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactS…
Revenue rose 10.2% year-over-year to JPY 1,219.9 billion, driven by yen depreciation, while core revenue was flat at constant exchange rates. Operating profit increased, but net profit declined due to higher tax and restructuring costs. FY2026 guidance expects modest revenue growth but lower core p…
Q1 FY2026 core revenue grew 10.2% YoY (flat at CER), with strong performance from new launches and core brands offsetting mature portfolio declines. Investments in transformative medicines and R&D continue, with full-year guidance reaffirmed and a focus on deleveraging and dividend growth.Original…
Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first quarter of fiscal year 2026 (April 1, 2026 to June 30, 2026), marking a period of disciplined execution and operational momentum. Takeda leveraged the resilient performance of its core in-line portfolio to support its long-term…
Explore more price target data and ratings for Takeda Pharmaceutical Company Limited on the Forecasts tab, and track all previous and future analyst recommendations for Takeda Pharmaceutical Company Limited in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactS…
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of D…
